Introducing 428Pharma.
Developing the world's first treatment to prevent relapse in depression
Preventing relapse in depression
1 in 2 patients
will relapse after their first episode of depression. After each new episode, the risk grows to 70% and 90% after the second and third.
Treatment Resistant Depression
up to 30% of TRD patients attempt suicide during their lifetime. Once a patient relapses 2x or more, they are classified as TRD which is much harder to treat
+56% suicides
Between 2007 and 2017, the suicide death rate among young people (ages 10-24) rose by 56%.
At 428 Pharma, we believe
Prevention of Relapse
is the most powerful form of treatment.
Relapse prevention can stop depression from progressing to treatment resistant and ultimately, help save lives.
Today, no approved therapies exist that effectively prevent relapse in Major Depressive Disorder (MDD).
428 Pharma is changing that.
Our Product
Escitalopram LAI (Long Acting Injectable)
428 Pharma develops a formulation of the worlds first LAI for prevention of relapse in MDD with a potential time to market 2028
-
First depot injection for SSRI for a vast depression market estimated at $15.8Bn in 2025
-
505(b)(2) truncated development with LOE 2046. PK only approval pathway under FDA
-
Opportunity to out-license end of phase I